Company profile page for Cardior Pharmaceuticals GmbH including stock price, company news, executives, board members, and contact information.

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.

Find the latest Cardiol Therapeutics Inc. (CRDL) stock quote, history, news and other vital information to help you with your stock trading and investing.

Cardior Pharmaceuticals has raised $92.3M over 3 rounds. Cardior Pharmaceuticals's latest funding round was a Acquired for on March 25, 2024.

Information on acquisition, funding, cap tables, investors, and executives for Cardior. Use the PitchBook Platform to explore the full profile.

Pharmaceuticals. Market Closed - Nasdaq Copenhagen. Other stock markets. 11:20 ... Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to $1.11 Billion.

25 мар. 2024 г. · Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has ...

25 мар. 2024 г. · Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and ...

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros, including an upfront payment and additional payments.

Cardior Pharmaceuticals, non-coding rna-based therapeutics in heart failure. Here you'll find information about their funding, investors and team.